Feb 28 |
TG Therapeutics reports Q4 results
|
Feb 28 |
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
|
Feb 28 |
Earnings Scheduled For February 28, 2024
|
Feb 27 |
TG Therapeutics Q4 2023 Earnings Preview
|
Feb 27 |
TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)
|
Feb 26 |
TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)
|
Feb 23 |
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update
|
Feb 21 |
Institutional owners may take dramatic actions as TG Therapeutics, Inc.'s (NASDAQ:TGTX) recent 6.8% drop adds to one-year losses
|
Feb 20 |
Will TG Therapeutics (TGTX) Report Negative Q4 Earnings? What You Should Know
|
Feb 20 |
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
|